% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mauriello:162747,
      author       = {Mauriello, Alessandro and Scimeca, Manuel and Amelio, Ivano
                      and Massoud, Renato and Novelli, Antonio and Di Lorenzo,
                      Francesca and Finocchiaro, Susanna and Cimino, Carolina and
                      Telesca, Rossana and Chiocchi, Marcello and Sun, Qiang and
                      Wang, Ying and Shi, Yufang and Novelli, Giuseppe and Melino,
                      Gerry},
      title        = {{T}hromboembolism after {COVID}-19 vaccine in patients with
                      preexisting thrombocytopenia.},
      journal      = {Cell death $\&$ disease},
      volume       = {12},
      number       = {8},
      issn         = {2041-4889},
      address      = {London [u.a.]},
      publisher    = {Nature Publishing Group},
      reportid     = {DZNE-2021-01403},
      pages        = {762},
      year         = {2021},
      note         = {CC BY},
      abstract     = {While vaccination is the single most effective intervention
                      to drastically reduce severe disease and death following
                      SARS-CoV-2 infection, as shown in UK and Israel, some
                      serious concerns have been raised for an unusual adverse
                      drug reaction (ADR), including vaccine-induced immune
                      thrombotic thrombocytopenia (VITT) with concurrent low
                      platelets as well as capillary leak syndrome. In fact, the
                      overall safety of the vaccine is highlighted by the low
                      frequency of ADR considering that in UK, by the early June,
                      40 million first doses and 29 million second doses have been
                      injected; nonetheless, 390 thrombotic events, including 71
                      fatal events have been reported. Interestingly, the cases
                      reported low platelet counts with the presence of
                      anti-platelet factor-4 (PF4) antibodies, indicating an
                      abnormal clotting reaction. Here, out of three referred
                      cases, we report a post-vaccine clinical case of fatal
                      thrombosis with postmortem examination and whole exome
                      sequencing (WES) analysis, whose pathogenesis appeared
                      associated to a preexisting condition of thrombocytopenia
                      due to myelodysplasia.},
      keywords     = {ChAdOx1 nCoV-19 / Bone Marrow: pathology / COVID-19:
                      prevention $\&$ control / COVID-19 Vaccines: adverse effects
                      / Fatal Outcome / Female / Humans / Lung: pathology / Middle
                      Aged / Myelodysplastic Syndromes: complications /
                      Myelodysplastic Syndromes: diagnosis / Myelodysplastic
                      Syndromes: pathology / SARS-CoV-2: immunology /
                      Thrombocytopenia: complications / Thrombocytopenia:
                      diagnosis / Thrombocytopenia: pathology / Thromboembolism:
                      etiology / COVID-19 Vaccines (NLM Chemicals) / ChAdOx1
                      COVID-19 vaccine (NLM Chemicals)},
      cin          = {AG Nicotera},
      ddc          = {570},
      cid          = {I:(DE-2719)5000018},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34344867},
      pmc          = {pmc:PMC8328816},
      doi          = {10.1038/s41419-021-04058-z},
      url          = {https://pub.dzne.de/record/162747},
}